Healthcare Services

Biologics Outsourcing Market to Reach $42.42B by 2030

April 17, 2026April 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Large Will The Biologics Outsourcing Market Be By 2030 Compared To Its 2026 Market Size?

The biologics outsourcing market has demonstrated rapid expansion in recent years. It is projected to increase from $22.58 billion in 2025 to $25.57 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. The historical growth of this market can be attributed to a combination of factors, including rising biologics commercialization activities, increasing capital intensity of biologics facilities, the expansion of biosimilar development programs, the growing complexity of regulatory compliance, and increasing collaboration between pharmaceutical companies and CDMOs.

The size of the biologics outsourcing market is anticipated to experience significant expansion over the coming years. This market is projected to reach $42.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. Factors contributing to this growth during the projected timeframe include a heightened need for extensive biologics production, increased funding in manufacturing facilities capable of handling multiple products, the expanding scope of cell and gene therapy outsourcing, a stronger emphasis on robust supply chains, and the wider implementation of digital manufacturing solutions. Key trends expected within the forecast period encompass a rise in the strategic outsourcing of biologic production, an escalating call for comprehensive end-to-end outsourcing services, an evolving preference for adaptable manufacturing collaborations, the enlargement of worldwide CDMO networks, and a heightened commitment to optimizing costs and mitigating risks.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

What Key Factors Are Shaping The Biologics Outsourcing Market Landscape?

The expanding occurrence of cancer cases is projected to drive the growth of the biologics outsourcing market moving forward. Cancer is a diverse group of illnesses that can emerge in virtually any organ or tissue within the body when atypical cells multiply unchecked, surpassing their usual boundaries, and either spreading to other organs or infiltrating adjacent body parts. Biologics outsourcing plays a vital role in addressing cancer cases by furnishing specialized expertise, resources, and infrastructure for the development, manufacturing, and clinical supply of biologic therapies, including monoclonal antibodies, immunotherapies, and other targeted biologics utilized for the diagnosis, treatment, and management of various cancer types. For instance, in January 2023, according to the National Center for Biotechnology Information, a US-based intergovernmental organization, there were 1,958,310 new cancer cases in the United States, and 609,820 cancer deaths are projected to occur in 2023. Furthermore, the annual number of new cancer cases is anticipated to climb to 29.5 million, and cancer-related deaths to 16.4 million by 2040. Therefore, the rising incidence of cancer cases is stimulating the growth of the biologics outsourcing market.

How Are Segments Identified Within The Biologics Outsourcing Market Segment Framework?

The biologics outsourcing market covered in this report is segmented –

1) By Product Type: Antibodies, Recombinant, Vaccines, Protein, Other Products

2) By Source: Human, Microbial, Other Sources

3) By Application: Oncology, Cellular And Gene Therapy, Blood And Blood-Related Products Development, Vaccine Development, Stem Cell Research, Other Applications

4) By End User: Pharmaceutical Industries, Biotechnology Industries, Contract Development And Manufacturing Organization (CDMO)

Subsegments:

1) By Antibodies: Monoclonal Antibodies, Polyclonal Antibodies

2) By Recombinant: Recombinant Proteins, Recombinant DNA Products

3) By Vaccines: Therapeutic Vaccines, Preventive Vaccines

4) By Protein: Enzymes, Hormones, Cytokines

5) By Other Products: Gene Therapies, Cell Therapies, Biosimilars

What Market Trends Are Affecting The Biologics Outsourcing Market?

Major companies operating in the biologics outsourcing market are prioritizing the establishment of new Contract Development and Manufacturing Organizations (CDMOs) to sustain their competitive edge. A CDMO offers a range of services to pharmaceutical and biotechnology companies, covering the development and manufacturing of drugs and other therapeutic products. For instance, in October 2023, Tanvex BioPharma USA Inc., a US-based developer and manufacturer of biopharmaceuticals, launched Tanvex CDMO. This new division delivers comprehensive services for the development and manufacturing of biologics, addressing the needs of the biopharmaceutical sector. Situated in San Diego’s Sorrento Valley biotech hub, Tanvex CDMO operates from a 100,000-square-foot facility. This facility includes a cutting-edge Research and Development (R&D) center, two mammalian Good Manufacturing Practice (GMP) manufacturing suites, one microbial GMP manufacturing suite, Quality Control (QC) laboratories, and a GMP warehouse. Leveraging the proven expertise of Tanvex BioPharma USA Inc., Tanvex CDMO aims to support early-stage companies in advancing mammalian and microbial-derived biologics from initial concept to market commercialization, thereby significantly boosting the fields of novel biologics and biosimilars.

Who Are The Companies Competing Within The Biologics Outsourcing Market?

Major companies operating in the biologics outsourcing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Lonza Group Ag, Catalent Inc., Sartorius Stedim Biotech S.A., Charles River Laboratories International Inc., WuXi Biologics Inc., Samsung Biologics Co. Ltd., Emergent BioSolutions Inc., CordenPharma GmbH, Ajinomoto Bio-Pharma Services, Syngene International Limited, Rentschler Biopharma SE, Albany Molecular Research Inc., KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies Inc., Avid Bioservices Inc., BioVectra Inc., ProBioGen AG, ABL Inc., Vibalogics GmbH, JHL Biotech Inc., Goodwin Biotechnology Inc., Crown Bioscience Inc., Cytovance Biologics Inc., LakePharma Inc., AGC Biologics GmbH, Biomay AG, Polpharma Biologics S.A.

Get The Full Biologics Outsourcing Market Report:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Which Region Is The Leading Market For The Biologics Outsourcing Market?

North America was the largest region in the biologics outsourcing market in 2025. The regions covered in the biologics outsourcing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Biologics Outsourcing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/biologics-outsourcing-global-market-report

Browse Through More Reports Similar to the Global Biologics Outsourcing Market 2026, By The Business Research Company

Medical Device Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/medical-device-outsourcing-global-market-report

Biologics Contract Development Market Report 2026

https://www.thebusinessresearchcompany.com/report/biologics-contract-development-global-market-report

Advanced Therapeutics Pharmaceutical Outsourcing Market Report 2026

https://www.thebusinessresearchcompany.com/report/advanced-therapeutics-pharmaceutical-outsourcing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795